4 King Street West
Suite 401
Toronto, ON M5H 1B6
Canada
888-223-9165
https://www.thiogenesis.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter:
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. Patrice P. Rioux M.D., Ph.D. | CEO & Director | 139,01k | N/A | 1951 |
Mr. Brook G. Riggins C.F.A. | CFO, Secretary & Director | 97,35k | 15k | 1966 |
Ms. Mary Jo Bagger | Consultant for Clinical Operations | N/A | N/A | N/A |
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-active therapeutic compounds to treat unmet medical needs. Its lead product candidate under development is TTI-0102, a prodrug consisting of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke, Rett syndrome, and pediatric non-alcoholic fatty liver diseases. The company is headquartered in Toronto, Canada.
Thiogenesis Therapeutics, Corp.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.